Moses H. Cone Memorial Hospital
Greensboro, North Carolina 27410
6 studies enrolling now · 28 studies all time
What they study most
Acute Decompensated Heart Failure, Acute Kidney Injury (AKI), Acute Respiratory Distress Syndrome, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atrial Enlargement, Atrial Fibrillation, Atrial Flutter, Cardiotoxicity, Cardiovascular Disease, Cardiovascular Diseases, Cerebrovascular Accident
Studies at this site
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
- AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor — Recruiting now
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery — Recruiting now
- Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258) — Recruiting now
- AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM — Recruiting now
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis — Running, not enrolling
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation — Completed
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
- AMPLATZER PFO Occluder Post Approval Study — Running, not enrolling
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
- SELUTION SLR™ 014 In-stent Restenosis — Running, not enrolling
- EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction — Running, not enrolling
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke — Stopped early
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) — Completed
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
- Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery — Completed
- ACP-01 in Patients With Critical Limb Ischemia — Completed
- Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure — Completed
- Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial — Completed
- Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass — Completed
- Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter — Completed
- Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) — Completed
- STIP: Statin Trial for Influenza Patients — Stopped early
- Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries — Completed
- Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) — Completed
- Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients — Completed